Barclays’s Marker Therapeutics MRKR Stock Holding History

Barclays’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-339	Closed	-$9K	–	4906
2021 Q2	$9K	Buy	+339	New	+$8.93K	﹤0.01%	4676
2020 Q3	–	Sell	-2,530	Closed	-$53K	–	5438
2020 Q2	$53K	Buy	+2,530	New	+$55.3K	﹤0.01%	4904
2020 Q1	–	Sell	-2,710	Closed	-$78K	–	6348
2019 Q4	$78K	Buy	+2,710	New	+$98.6K	﹤0.01%	5588
2019 Q3	–	Sell	-2,797	Closed	-$221K	–	6977
2019 Q2	$221K	Sell	2,797 -10,262	-79%	-$610K	﹤0.01%	5018
2019 Q1	$862K	Sell	13,059 -2,953	-18%	-$172K	﹤0.01%	3567
2018 Q4	$889K	Buy	16,012 +15,432	+2,661%	+$1.12M	﹤0.01%	3244
2018 Q3	$52K	Sell	580 -220	-28%	-$18.9K	﹤0.01%	6057
2018 Q2	$75K	Buy	+800	New	+$40.8K	﹤0.01%	5422
2018 Q1	–	Hold	0	–	–	–	7230

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Barclays's MRKR Position: Q3 2021 in Review

Barclays sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 339 shares — an estimated $9K sold.

Barclays first reported a position in MRKR in Q2 2018 and held it in 8 quarters. The position peaked at $889K in Q4 2018. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

Barclays reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
Barclays sold 339 Marker Therapeutics shares in Q3 2021, an estimated $9K.
Barclays first reported a position in Marker Therapeutics in Q2 2018 and held it in 8 quarters.
Barclays's Marker Therapeutics position peaked at $889K in Q4 2018.
63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.